本文選題：microRNA21 + 乳腺癌��； 參考：《山西醫(yī)科大學(xué)》2017年碩士論文

【摘要】：目的:采用Meta分析系統(tǒng)評價乳腺癌患者中microRNA21的高表達與其臨床病理特征之間的相關(guān)關(guān)系,為人們對乳腺癌的臨床診療思維帶來新的啟迪與深化。方法:使用互聯(lián)網(wǎng)檢索英文數(shù)據(jù)庫pubmed、medline、embase以及中文數(shù)據(jù)庫中國知網(wǎng)、萬方數(shù)據(jù)庫、維普數(shù)據(jù)庫等相關(guān)數(shù)據(jù)庫,根據(jù)一定的檢索方法,網(wǎng)羅國外和國內(nèi)公開發(fā)表的所有關(guān)于乳腺癌中microRNA21的高表達與乳腺癌發(fā)病特征及臨床病理資料的相關(guān)性的文獻,對契合既定的納入標準的文獻篩選,然后對其中所要用到的相關(guān)數(shù)據(jù)進行統(tǒng)計歸納。檢索年限分別從相關(guān)數(shù)據(jù)庫創(chuàng)建開始,結(jié)束時間是2016年10月31日。應(yīng)用Review Manager5.3軟件進行Meta分析,提取的數(shù)據(jù)采用比值比(odds ratio,OR),OR的95%可信區(qū)間(confidence interval,CI)來表示,根據(jù)計算結(jié)果繪制相關(guān)指標的森林圖,通過漏斗圖進行發(fā)表偏倚的評價,并對文獻進行敏感性分析,采用合適的效應(yīng)模型對數(shù)據(jù)進行統(tǒng)計分析,以P=0.05為檢驗水準,如果P0.05可視為差異有統(tǒng)計學(xué)意義。結(jié)果:本次薈萃分析共納入10篇參考文獻,有1270名符合標準的乳腺癌患者。Meta分析結(jié)果:月經(jīng)狀態(tài)(是否絕經(jīng)):OR=1.66,95%CI為0.93-2.93,P=0.08;腫瘤直徑大小(2cm):(OR=1.57,95%CI為0.81-3.02,P=0.18);組織學(xué)分級(II、III級與I級):OR=3.59,95%CI為1.92-6.74,P0.0001,(III級與I、II級):OR=2.08,95%CI為1.15-3.76,P=0.01;淋巴結(jié)的轉(zhuǎn)移:OR=2.45,95%CI為1.92-3.13,P0.0001;腫瘤TNM分期:OR=2.46,95%CI為1.67-3.62,P0.0001;人類表皮生長因子受體2(Her-2):OR=1.95,95%CI為1.47-2.58,P0.0001;ER:OR=0.99,95%CI0.56-2.90P=0.08;PR:OR=1.12,95%CI0.54-2.32,P=0.75。結(jié)論:1.乳腺癌患者中,microRNA21的高表達與腫瘤的較高的組織學(xué)分級、淋巴結(jié)陽性轉(zhuǎn)移、臨床高TNM分期、Her2陽性表達有相關(guān)性,與月經(jīng)狀態(tài)、腫瘤大小、ER陽性表達、PR陽性表達無相關(guān)性。2.miR-21的表達情況可作為乳腺癌篩查及術(shù)前檢查的一種標記物,在對乳腺癌預(yù)后判斷以及制定合理的個體化治療方面具有很大的潛力。
[Abstract]:Objective: to evaluate the correlation between the high expression of microRNA21 and its clinicopathological features in breast cancer patients by Meta-analysis system, and to bring new enlightenment and deepening to the clinical diagnosis and treatment thinking of breast cancer. Methods: the English database pubmedmedlineembase and the Chinese databases, such as China Zhiwang, Wanfang and Weipu databases, were searched on the Internet. To include all published foreign and domestic literature on the correlation between the high expression of microRNA21 in breast cancer and the characteristics and clinicopathological data of breast cancer, and to screen the literature that conforms to the established inclusion criteria, Then the relevant data to be used in statistical induction. The retrieval period starts with the creation of the related database and ends on October 31, 2016. Meta-analysis was carried out with the software Review Manager 5.3. The extracted data were expressed by 95% confidence intervalor of odds ratio. Forest maps of relevant indicators were drawn according to the calculated results, and publication bias was evaluated by funnel maps. And the sensitivity of the literature analysis, using the appropriate effect model for statistical analysis of the data, with P0. 05 as the test level, if P0.05 can be regarded as the difference has statistical significance. Results: a total of 10 references were included in this meta-analysis. 鏈，

本文編號：2034908